Skip to content Skip to footer
Genmab & Pfizer

Genmab and Pfizer Secure the EC’s Approval for Tivdak (Tisotumab Vedotin) for Recurrent or Metastatic Cervical Cancer

Shots:The EC has approved Tivdak an ADC, as a monotx. for adults (n=502) with recurrent or metastatic cervical cancer with disease progression on or after systemic therapyApproval was backed by P-III (innovaTV 301) global trial evaluating Tivdak vs CT alone (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)The trial met its 1EP of OS,…

Read more

VIEWPOINTS_Michael Moran1_Julie Blaedel2_2024

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Shots:   Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL  Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…

Read more

VIEWPOINTS_Tahi Ahmadi1_Asud Khaliq2_2023

Tahi Ahmadi and Asud Khaliq Share their Views on EPKINLY (epcoritamab) U.S. FDA Approval in DLBCL

Shots:Tahi and Asud initiated the conversation with an overview of EPKINLYTM (epcoritamab) and its approval by the U.S. FDA to treat R/R DLBCLThey then spoke about the study design and results from the EPCORE NHL-1 P-I/II trial that served as the basis for the U.S. FDA approval of EPKINLY.EPKINLY is being co-developed and co-commercialized by Genmab and AbbVie. Both companies are evaluating…

Read more

PharmaShots Interview Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

Shots: Laurent spoke about the study design of its nanoparticle therapy to enhance the cancer-killing effect of radiation, which was presented at ASCO 2022Laurent also highlighted how this nanoparticle therapy can be a potential radio enhancer in various tumor types and across lines of therapyThe interview summarizes Nanobiotix’s vision to advance nanoparticles across…

Read more